Foley & Lardner Warns Device Makers on U.S. Compliance Risk
In a Foley & Lardner LLP client alert, the firm argues that medical device companies entering the U.S. market should prioritize corporate compliance programs given active DOJ and HHS-OIG enforcement under the False Claims Act, Anti-Kickback Statute, and Foreign Corrupt Practices Act. The firm cites settlements including ResMed ($37.5 million, 2020), Innovasis ($12 million, 2024), Aesculap Implant Systems ($38.5 million, 2025), and Diopsys ($14.25 million, 2025), covering kickbacks to providers, off-label promotion, and false claims to Medicare and Medicaid. The firm recommends building compliance programs around OIG's seven elements and focusing on provider financial relationships, promotional and billing practices, distributor oversight, and transfer-of-value reporting.